Lilly ICOS LLC to Release Financial Results for 2006
January 04 2007 - 8:00AM
Business Wire
Lilly ICOS LLC (Lilly ICOS) (NYSE:LLY) (Nasdaq:ICOS) will announce
its fourth quarter and 2006 full year financial results after the
U.S. markets close on January 18, 2007. About Lilly Lilly, a
leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers - through medicines and information - for some of the
world's most urgent medical needs. Additional information about
Lilly is available at www.lilly.com. F-LLY About ICOS ICOS
Corporation, a biotechnology company headquartered in Bothell,
Washington, is dedicated to bringing innovative therapeutics to
patients. Through Lilly ICOS LLC, ICOS is marketing its first
product, Cialis(R) (tadalafil)1, for the treatment of erectile
dysfunction. ICOS is working to develop treatments for serious
unmet medical needs such as benign prostatic hyperplasia, pulmonary
arterial hypertension, cancer, psoriasis and inflammatory diseases.
Except for historical information contained herein, this press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on current expectations,
estimates and projections about the industry, management beliefs
and certain assumptions made by the managements of ICOS and Lilly.
Investors are cautioned that matters subject to forward-looking
statements involve risks and uncertainties, including economic,
competitive, governmental, technological, legal and other factors
discussed in the two companies� respective filings with the
Securities and Exchange Commission, which may affect the business
and prospects of the two companies and Lilly ICOS. Results and the
timing and outcome of events may differ materially from those
expressed or implied by the forward-looking statements in this
press release. More specifically, there can be no assurance that
Cialis will achieve sustained commercial success or that competing
products will not pre-empt market opportunities that might exist
for the product. The forward-looking statements contained in this
press release represent ICOS� and Lilly�s judgments as of the date
of this release. Neither ICOS nor Lilly undertake any obligation to
update any forward-looking statements. 1 Cialis� is a registered
trademark of Lilly ICOS LLC.
Icos (NASDAQ:ICOS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Icos (NASDAQ:ICOS)
Historical Stock Chart
From Oct 2023 to Oct 2024